Anesthesia for radical resection of ovarian cancer

Influence of etomidate combined with transversus abdominis plane block on serum-related factors and immune function in patients undergoing radical resection of ovarian cancer

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN10813814

Enrollment

Registered

2026-05-08

Start date

2022-09-01

Completion date

Unknown

Last updated

2026-05-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ovarian cancer patients undergoing radical resection surgery Cancer

Interventions

Participants were randomly assigned to the control group or research group using a random number table method. Control group: Total intravenous anesthesia (TIVA) combined with etomidate was administe

Eligibility

Sex/Gender

Female

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Patients diagnosed with ovarian cancer confirmed by pathological biopsy 2. Patients undergoing radical resection of ovarian cancer 3. ASA physical status I–III 4. Complete clinical data available 5. Normal cognitive function and ability to communicate

Exclusion criteria

Exclusion criteria: 1. Patients with other malignant tumors 2. Patients with hematological diseases 3. Patients with immune system disorders 4. Patients with severe dysfunction of heart, liver, lung, kidney, or other major organs 5. Pregnant or lactating women 6. Patients with coagulation disorders or bleeding tendency 7. Patients with contraindications to anesthesia

Countries

China

Contacts

Public ContactFeng Jian

jianfengzch@csc-edu.cn+86-533-2360475

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: May 22, 2026